SILK Stock Overview
Silk Road Medical, Inc. operates as a medical device company in the United States.
Silk Road Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$29.32|
|52 Week High||US$67.49|
|52 Week Low||US$27.21|
|1 Month Change||-26.94%|
|3 Month Change||-7.13%|
|1 Year Change||-39.94%|
|3 Year Change||-35.36%|
|5 Year Change||n/a|
|Change since IPO||-18.96%|
Recent News & Updates
|SILK||US Medical Equipment||US Market|
Return vs Industry: SILK underperformed the US Medical Equipment industry which returned -16.7% over the past year.
Return vs Market: SILK underperformed the US Market which returned -13.2% over the past year.
|SILK Average Weekly Movement||11.8%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: SILK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: SILK's weekly volatility (12%) has been stable over the past year.
About the Company
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices.
Silk Road Medical Fundamentals Summary
|SILK fundamental statistics|
Is SILK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SILK income statement (TTM)|
|Cost of Revenue||US$28.49m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.59|
|Net Profit Margin||-51.93%|
How did SILK perform over the long term?See historical performance and comparison
Is Silk Road Medical undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SILK's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SILK's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: SILK is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Medical Equipment industry average.
PE vs Market: SILK is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SILK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SILK is overvalued based on its Price-To-Book Ratio (15.2x) compared to the US Medical Equipment industry average (2.4x).
How is Silk Road Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SILK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SILK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SILK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SILK's revenue (24% per year) is forecast to grow faster than the US market (7.7% per year).
High Growth Revenue: SILK's revenue (24% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SILK is forecast to be unprofitable in 3 years.
How has Silk Road Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SILK is currently unprofitable.
Growing Profit Margin: SILK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SILK is unprofitable, and losses have increased over the past 5 years at a rate of 7.6% per year.
Accelerating Growth: Unable to compare SILK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SILK is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).
Return on Equity
High ROE: SILK has a negative Return on Equity (-82.41%), as it is currently unprofitable.
How is Silk Road Medical's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SILK's short term assets ($127.8M) exceed its short term liabilities ($29.5M).
Long Term Liabilities: SILK's short term assets ($127.8M) exceed its long term liabilities ($45.8M).
Debt to Equity History and Analysis
Debt Level: SILK has more cash than its total debt.
Reducing Debt: Insufficient data to determine if SILK's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SILK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SILK has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 16.7% each year.
What is Silk Road Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SILK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SILK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SILK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SILK's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SILK has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Erica Rogers (57 yo)
Ms. Erica J. Rogers serves as the Chief Executive Officer and President of Silk Road Medical Inc since October 2012. Ms. Rogers serves as Independent Director at Sight Sciences, Incorporated since November...
CEO Compensation Analysis
Compensation vs Market: Erica's total compensation ($USD3.32M) is about average for companies of similar size in the US market ($USD3.95M).
Compensation vs Earnings: Erica's compensation has increased whilst the company is unprofitable.
Experienced Management: SILK's management team is considered experienced (4.2 years average tenure).
Experienced Board: SILK's board of directors are considered experienced (6.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Silk Road Medical, Inc's employee growth, exchange listings and data sources
- Name: Silk Road Medical, Inc
- Ticker: SILK
- Exchange: NasdaqGS
- Founded: 2007
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$1.030b
- Shares outstanding: 35.12m
- Website: https://silkroadmed.com
Number of Employees
- Silk Road Medical, Inc
- 1213 Innsbruck Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.